Patient Group to House Democrats: Don’t Cut Bad Deal with Big Pharma

June 11, 2018 Press Releases

WASHINGTON, D.C. — “Don’t Get Fooled Again.” That’s the message from cancer patient and founder and president of Patients For Affordable Drugs David Mitchell to 50 Democratic members of the House. The members all signed on to a letter supporting drug corporations’ lobbying efforts to rollback Big Pharma’s contribution to Medicare that saves patients and taxpayers money.

Big Pharma’s list prices are crushing America’s seniors

June 4, 2018 Press Releases

WASHINGTON, DC — Seniors are filling fewer prescriptions for brand-named drugs, but they’re spending significantly more because list prices keep going up, according to a new government report. In response, David Mitchell, a cancer patient and founder of Patients For Affordable Drugs, issued the following statement.

ICYMI: A Push for Affordable Prices for Taxpayer-Funded Drugs

May 29, 2018 News, Press Releases

“We have an incredibly powerful, incredibly productive research and development program being run by N.I.H.,” Ameet Sarpatwari, an instructor at Harvard Medical School, said. “Taxpayers put in money that is paying big dividends, and yet we pay higher prices for prescription drugs than any other country. In effect, we have taxpayers paying twice.”

Patients For Affordable Drugs Joins Cystic Fibrosis Patients to Demand That Vertex Lower Its Drug Prices

May 17, 2018 Press Releases

St. Louis — Patients For Affordable Drugs stood with Lora Moser, a cystic fibrosis patient unable to afford the medicines her family spent decades fundraising to develop, and launched a new campaign demanding that Vertex Pharmaceuticals lower the price of its life-extending drugs.

Moser and Patients For Affordable Drugs were represented Thursday at a meeting of the Institute For Clinical and Economic Review (ICER) by Juliana Keeping, mother to Eli, 5, who also has cystic fibrosis.

JOIN US

Patients For Affordable Drugs is the only independent national patient organization focused exclusively on achieving policy changes to lower the price of prescription drugs.